CYRX Cryoport, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1124524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.8%
TTM net income YoY-157.9%
TTM EPS YoY-178.6%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR—
Margins
Gross margin46.9%
Operating margin-20.0%
Net margin-21.5%
FCF margin-9.8%
EBITDA margin-6.6%
Returns
ROE-8.3%
ROA-5.4%
ROIC (approx.)-13.2%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets35.6%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-18.32x
Cash quality & payout
Operating cash flow / net income-0.27x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue15.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $50.22M | $48.97M | $47.80M | $45.45M | $44.23M | $45.45M | $41.04M | $41.45M |
| Cost of revenue | $26.39M | $26.15M | $25.89M | $23.74M | $22.91M | $24.08M | $22.40M | $21.96M |
| Gross profit | $23.83M | $22.82M | $21.91M | $21.71M | $21.32M | $21.38M | $18.64M | $19.49M |
| R&D expense | $4.73M | $4.85M | $3.91M | $4.47M | $4.52M | $4.12M | $3.93M | $4.16M |
| SG&A expense | $27.90M | $28.01M | $27.62M | $27.28M | $26.73M | $26.91M | $21.90M | $28.08M |
| Operating income | -$8.80M | -$10.04M | -$9.61M | -$10.03M | -$9.93M | -$9.65M | -$7.19M | -$12.74M |
| Interest expense | $517,000 | $518,000 | $432,000 | $634,000 | $526,000 | $618,000 | $583,000 | $579,000 |
| Pretax income | -$10.66M | -$7.75M | -$9.32M | -$7.39M | -$6.53M | -$11.74M | -$6.50M | -$17.31M |
| Income tax | $194,000 | $505,000 | $108,000 | $1.13M | $165,000 | $274,000 | $234,000 | -$134,000 |
| Net income | -$10.85M | -$8.26M | -$10.54M | -$11.64M | -$6.94M | $108.87M | -$11.98M | -$18.68M |
| EBITDA | -$2.34M | -$3.45M | -$3.21M | -$3.68M | -$3.52M | -$2.35M | $452,000 | -$4.85M |
| EPS (basic) | -0.25 | -0.20 | -0.25 | — | -0.18 | 2.13 | -0.28 | — |
| EPS (diluted) | -0.25 | -0.20 | -0.25 | — | -0.18 | 2.13 | -0.28 | — |
| Weighted avg. shares (diluted) | 50.65M | 50.44M | 49.90M | — | 50.13M | 50.26M | 49.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $279.18M | $269.27M | $272.91M | $250.49M | $255.81M | $243.42M | $36.10M | $34.14M |
| Short-term investments | $113.90M | $127.43M | $130.72M | $160.71M | $165.50M | $182.56M | $207.93M | $216.46M |
| Receivables | $36.00M | $36.45M | $39.00M | $33.36M | $34.91M | $33.41M | $28.37M | $25.30M |
| Inventory | $22.44M | $21.51M | $21.75M | $23.19M | $23.33M | $23.04M | $23.34M | $21.48M |
| Current assets | $456.70M | $460.20M | $470.54M | $476.17M | $484.84M | $489.49M | $411.28M | $341.57M |
| PP&E, net | $96.37M | $94.52M | $89.81M | $85.45M | $83.23M | $81.56M | $80.48M | $80.01M |
| Goodwill | $22.03M | $22.07M | $22.14M | $22.40M | $22.41M | $18.71M | $20.96M | $20.57M |
| Intangibles | $133.28M | $135.99M | $138.72M | $138.08M | $141.25M | $143.59M | $145.41M | $147.93M |
| Total assets | $750.95M | $756.20M | $763.61M | $764.99M | $774.33M | $773.93M | $699.84M | $703.49M |
| Current liabilities | $224.18M | $221.04M | $224.87M | $219.02M | $30.75M | $30.15M | $74.03M | $64.56M |
| Total liabilities | $267.43M | $265.50M | $268.62M | $262.35M | $261.06M | $258.54M | $301.03M | $301.59M |
| Shareholders' equity | $483.51M | $490.70M | $494.99M | $502.64M | $513.27M | $519.08M | $398.81M | $401.90M |
| Shares outstanding | 50.69M | 50.65M | 50.20M | 49.85M | 50.07M | 50.28M | 50.14M | 49.91M |
| Cash flow statement | ||||||||
| Operating cash flow | $5.21M | $1.13M | $3.73M | $919,000 | $2.19M | -$7.34M | -$4.34M | -$5.48M |
| Capital expenditure | $5.25M | $9.10M | $9.98M | $5.47M | $3.45M | $4.35M | $3.17M | $5.22M |
| Free cash flow | -$40,000 | -$7.97M | -$6.25M | -$4.55M | -$1.26M | -$11.70M | -$7.51M | -$10.70M |
| Investing cash flow | $4.17M | -$5.81M | $18.72M | $56,000 | $14.31M | $230.04M | $5.92M | $3.48M |
| Financing cash flow | $216,000 | $653,000 | $85,000 | -$2.15M | -$2.87M | -$15.86M | -$189,000 | $2.01M |
| Depreciation & amortization | $6.47M | $6.59M | $6.40M | $6.36M | $6.42M | $7.30M | $7.65M | $7.89M |
| Stock-based compensation | $2.35M | $2.40M | $2.40M | $2.43M | $2.53M | $2.04M | $3.06M | $3.64M |
| Share buybacks | — | — | — | $2.01M | $3.75M | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.